Not applicableApproved For MarketingNCT03843892
What this trial is testing
An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
Who this might be right for
Lung Diseases, Interstitial
Boehringer Ingelheim